Clik here to view.
Data Protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1...
The Trans Pacific Partnership (TPP) negotiation does not yet include a section on data protection (typically included in the Pharmaceutical Chapter of Free Trade Agreements). Organizations against the...
View ArticleClik here to view.
Data Protection, Trans Pacific Partnership, and the US-Jordan FTA (Post 2 of 2)
This post is a continuation of a previous post: Data Protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1 of 2). 4. Oxfam criticizes pharmaceutical innovators for not making all of...
View ArticleClik here to view.
Bi-partisan Senate Letter asking for 12 years of Data Protection in TPP
Senators Hatch and Kerry, along with 35 other Senators, sent a letter to Ambassador Kirk asking for 12 years of regulatory data protection consistent with U.S. law in the Trans Pacific Partnership...
View ArticleClik here to view.
TPP and Innovation in the Bioeconomy: The Need for 12 Years of Data Protection
A few weeks ago, BIO submitted a letter and white paper (PDF) to the U.S. Trade Representative outlining recommendations for policies to pursue with TPP negotiating partners to ensure intellectual...
View ArticleClik here to view.
TPP and IP: The Economic Benefits of a Pacific Trade Agreement
Ndp Analytics recently published a study on the economic benefits of intellectual property rights (IP) in the Trans-Pacific Partnership. They find that 2/3’s of the “economic benefits for the U.S....
View ArticleClik here to view.
New Report Suggests RDP Does Not Increase Healthcare Expenditures
A new paper by the Geneva Network suggests that increasing the period of regulatory data protection (RDP) for biologic medicines would not increase expenditures for medicines. As countries navigate the...
View ArticleClik here to view.
WSJ: U.S. Concessions on TPP Means Fewer Cures
Today’s Wall Street Journal editorial, Pacific Trade Brinksmanship, does an outstanding job highlighting the important role that patent protection plays in promoting innovation and fostering medical...
View ArticleBiotech Policy Outlook at #BIF15: 21st Century Cures, IPR, TPP, and PDUFA VI
To even the most casual observer, 2015 has been a big year in the biotech industry, particularly in Congress and in other venues wherein public policies that affect the sector take shape. Given the...
View Article
